These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34028566)

  • 1. PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients.
    Wang Y; Chen H; Jiao X; Wu L; Yang Y; Zhang J; Wu L; Liu C; Zhuo N; Li S; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Lu Z; Zhang H; Shen L
    Cancer Immunol Immunother; 2022 Jan; 71(1):111-120. PubMed ID: 34028566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTCH1 mutation as a potential predictive biomarker for immune checkpoint inhibitors in gastrointestinal cancer.
    Deng S; Gu H; Chen Z; Liu Y; Zhang Q; Chen D; Yi S
    Carcinogenesis; 2024 May; 45(5):351-357. PubMed ID: 38310539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
    Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
    Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy.
    Sibilio P; Belardinilli F; Licursi V; Paci P; Giannini G
    Biol Direct; 2022 May; 17(1):10. PubMed ID: 35534873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1.
    Sveen A; Johannessen B; Tengs T; Danielsen SA; Eilertsen IA; Lind GE; Berg KCG; Leithe E; Meza-Zepeda LA; Domingo E; Myklebost O; Kerr D; Tomlinson I; Nesbakken A; Skotheim RI; Lothe RA
    Genome Med; 2017 May; 9(1):46. PubMed ID: 28539123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
    Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
    Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
    Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
    Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
    BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
    Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
    J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of FAT1 mutations to indicate the immune response in colorectal cancer patients.
    Zhu W; Yang L; Gao Y; Zhou Y; Shi Y; Liu K; Yu R; Shao Y; Zhang W; Wu G; He J
    Genomics; 2024 Mar; 116(2):110808. PubMed ID: 38364976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
    Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
    Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADAMTSL2 is a potential prognostic biomarker and immunotherapeutic target for colorectal cancer: Bioinformatic analysis and experimental verification.
    Huang Z; Hu X; Wei Y; Lai Y; Qi J; Pang J; Huang K; Li H; Cai P
    PLoS One; 2024; 19(5):e0303909. PubMed ID: 38814950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
    Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
    PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.